Sign In to Follow Application
View All Documents & Correspondence

Composition Comprising Climbazole Fungicide And Zinc Gluconate

Abstract: Hair treatment composition comprising an azole fungicide and zinc gluconate and wherein the composition does not comprise Trichogen®.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
10 October 2011
Publication Number
05/2012
Publication Type
INA
Invention Field
CHEMICAL
Status
Email
Parent Application
Patent Number
Legal Status
Grant Date
2017-03-29
Renewal Date

Applicants

HINDUSTAN UNILEVER LIMITED
HINDUSTAN LEVER HOUSE, 165-166 BACKBAY RECLAMATION, MUMBAI, 400 020, INDIA

Inventors

1. BURRY JASON SHAUN
UNILEVER R&D PORT SUNLIGHT, QUARRY ROAD EAST, BEBINGTON, WIRRAL, MERSEYSIDE CH63 3JW, UNITED KINGDOM
2. EVANS RICHARD LIVESEY
UNILEVER R&D PORT SUNLIGHT, QUARRY ROAD EAST, BEBINGTON, WIRRAL, MERSEYSIDE CH63 3JW, UNITED KINGDOM
3. TURNER GRAHAM ANDREW
UNILEVER R&D PORT SUNLIGHT, QUARRY ROAD EAST, BEBINGTON, WIRRAL, MERSEYSIDE CH63 3JW, UNITED KINGDOM

Specification

FORM - 2
THE PATENTS ACT, 1970
(39 of 1970)
&
The Patents Rules, 2003
COMPLETE SPECIFICATION
(See Section 10 and Rule 13)
COMPOSITION COMPRISING A20LE FUNGICIDE AND WATER SOLUBLE METAL SALT
HINDUSTAN UNILEVER LIMITED, a company incorporated under
the Indian Companies Act, 1913 and having its registered office
at 165/166, Backbay Reclamation, Mumbai -400 020, Maharashtra, India
The following specification particularly describes the invention and the manner in which it is to be performed

COMPOSITION COMPRISING AZOLE FUNGICIDE AND WATER SOLUBLE METAL SALT
The present invention relates to compositions ior treating or preventing hair fail.
Despite the prior art there remains a need for improved compositions for treating or preventing hair fail.
Accordingly, there is provided a hair treatment composition comprising an azole fungicide and zinc gluconate, and wherein the composition does not comprise Trichogen® Veg LS 8960.
Preferably, the azole fungicide is clirnabazole or ketoconazole.
Preferably, the azole is present at from 0.0001 to 1 % wt. of the composition.
Preferably, the zinc gluconate is present at from 0.001 to 2% wt. of the composition. More preferably, the composition comprises from 0.005 to 1% wt. of the composition.
Preferably, the composition does not comprises a synergistic mixture of a healthy scalp protein biosynthesis stimulant, a glycosamino production agent, a cell nutrition regulator, a microcirculation promotor and mixtures thereof.
Preferably the composition does not comprises a synergistic trichogenic mixture of a protein biosynthesis stimulant selected from a sulfopeptide of soy, amino acids, glutamine, glutamic acid, hydrolysed protein extracts, particularly sulfopeptides of soy and amino acids, especially tyrosine, arginine, ornithine and citrulline. Preferably, the composition does not comprise a glycosamino production agent selected from the group consisting of glucosamine, L-fucose; fucose rich polysaccharide, xylose, vitamin C, Eriobotrya japonica extract, N-acetyl

giucosamine, glucosamine sulphate, lysophospholipids, protamine and mixtures thereof. Particularly preferred is glucosamine.
Preferably, the composition does not comprise a ceil nutrition regulator especially vitamins of the B group, carnitine, co-enzyme Q10, creatine, taurine, acetyl-carnitine and mixtures thereof. Particularly preferred are vitamins of the B group, especially PP, B5 and biotin,
Preferably, the composition does not comprise a microcirculation promoter, more preferably a microcirculation promoter selected from Panax Ginseng Extract, Arctium Majus Extract, nitric oxide, niacin, caffeine, gingko biloba extract, bicyclic monoterpene diols, a-lipoic acid, ximenynic acid, proanthocyanidins, arginine and mixtures thereof.
Preferably, the composition does not comprise a protein biosynthesis stimulant selected from a suJfopeptide of soy, amino acids, glutamine, glutamic acid, hydrolysed protein extracts.
Preferably, the composition does not comprise a glycosamino production agent selected from giucosamine, L-fucose; fucose rich polysaccharide xylose.vitamin C, Eriobotrya Japonica extract, N-acety! glucosamine, glucosamine sulphate, lysophospholipids, protamine and mixtures thereof.
Preferably, the composition does not comprise a cell nutrition regulator is selected from vitamins of the B group, carnitine, co-enzyme Q10, creatine, taurine, acetyf-carnitine and mixtures thereof.
Preferably, the composition does not comprise a microcirculation promoter is selected from Panax Ginseng Extract, Arctium Majus Extract nitric oxide, niacin,

caffeine, gingko biioba extract, bicyclic monoterpene diols, a-lipoic acid, ximenynic acid, proantnocyanidins, arginine and mixtures thereof,
Most preferably, the composition does not comprise Trichogen® ex Cognis, in particular Trichogen® Veg LS 8960.
Trichogen® Veg LS 8960. contains:
Panax Ginseng Root Extract, Arginine, Acetyl Tyrosine, Arctium Majus Root Extract, Hydroiysed Soy Protein, Zinc gluconate, Niacinamide, Biotin, Salvia Scfarea Extract, Cinnamomumb Zeyianrcurn Extract, Ginko Biioba Extract and Kigela Africana Extract.
The composition according to the invention may be in any product form, e.g. shampoo, mousse, conditioner, gel, mask and may be a rinse-off product or a leave-on product.
Depending on product form the composition according to the invention may aiso comprise any common ingredients typically found in such product form. For example, a shampoo will likely comprise cleansing surfactants; a conditioner will comprise conditioning agents selected from fatty alcohols, silicone and cationic surfactants, etc.
The invention will now be described with reference to the following embodiments.
EXAMPLE 1
The following are formulations according to embodiments of the invention.

Leave-on formulations

A B c D E F
Water and minors To 100% To 100% To 100% To 100% To 100% To 100%
Nafrosoi 250HHR 1.00 1.00 1.00 1.00 1.00 1.00
Glycerol 5.00 5.00 5.00 5.00 5.00 5.00
Zinc
gluconate 0.1 0.1 0.05 0.05 0.001 0.006
ClimbazoJe 0,02 0.001 0.02 0.001 0.008 0.06
Ethanol 1.0 1.0 1.0 1.0 1.0 1.0
Shamooo examples

Water and minors To 100% To 100% To 100% To 100%
Climbazole 0.5 0.5 0.5 0.5
Zinc gluconate 1.0 0.8 0.4 0.5
Texapon N70 7.70 7.70 7.70 7.70
Mackanate EL 12.50 12.50 12.50 12.50
Tegobetaine 9.60 9.60 9.60 9.60
Jaguar C13S 0.15 0.15 0.15 0.15
Jaguar C17 0.05 0.05 0.05 0.05
Sodium Hydroxide (50%) 0.05 0.05 0.05 0.05

Conditioners

Water To 100% To 100%
Lexamine S13 1.25 1.25
Ganamin BTLF 1.25 1.25
Laurex CS 5.00 5.00
Potassium Chloride 0.10 0.10
EDTA 0.10 0.10
Laurie Acid 0.30 0.30
Zinc gluconate 1.0 1.0
Climbazole 0.5 0.2
Propylene glycol 2.0 2.0
EXAMPLE 2
The following shows how zinc gluconate and climbazole provide an improved anti-trypsin effect.

1. Zinc Gluconate (0.00156%) plus climbazole

Ingredient Normalised activity
Control 1.0 1.0 1.0 1.0 1.0 1.0
(Trypsin only)
a. Climbazole 1.15
0.00391%
b. Climb 131
0.00781%
c. Climb 1.41
0.01563%
d. Climb 1.30
0.03125%
e, Climb 0.908
0.0625%
f. Climb 0.125% 1.06
g. Zinc 1.03 1.03 1.03 1.03 1.03 1.03
gluconate
(0.00156%)
Calculated 1,045 0.969 1.165 1.22 1.17 1.09
efficacy
Experimental
efficacy 0.935 0.88 0.32 0.49 0.75 0.93
(synergy)

2, Zinc Gluconate (0.003125%) plus climbazole

Ingredient Normalised activity
Control 1.0 1.0 1.0 | 1.0 1.0 1,0
(Trypsin only)
a. Climbazole 1.15
0.00391%
b. Climb 1.31
0.00781%
c. Climb 1.41
0.01563%
d. Climb 1.30
0.03125%
e. Climb 0.908
0.0625%
f. Climb 0.125% 1.06
g. Zinc 0.957 0.957 0.957 0.957 0.957 0.957
gluconate
(0.003125%)
Calculated 1.01 0.9325 1.1285 1.1835 1.1335 1.0535
efficacy
Experimental
efficacy 0.87 0.88 0.24 0.27 0.61 0.83
(synergy)

3. Zinc Gluconate (0,00625%) plus clirnbazole

Ingredient Normalised activity
Control 1.0 1.0 1.0 1.0 1.0 1.0
(Trypsin only)
a. Clirnbazole 1.15
0.00391 %
b, Climb 1.31
0.00781%
C Climb 1.41
0.01563%
d. Climb 1.30
0.03125%
e. Climb 0.908
0.0625%
f. Climb 0.125% 1.06
g.Zinc 0.8404 0.8404 0.8404 0.8404 0.8404 0.8404
. gluconate
(0.00625%)
Calculated 0.95 0.874 1.07 1.125 1.075 0.995 ;
efficacy
Experimental
efficacy 0.753 1.10 0.328 0.037 0.384 0.578
(synergy)

CLAIMS
1. Hair treatment composition comprising an azole fungicide and zinc gluconate and wherein the composition does not comprise Trichogen®.
2. Hair treatment composition according to claim 1 wherein the azole fungicide is climabazole or ketoconazole.

Documents

Orders

Section Controller Decision Date

Application Documents

# Name Date
1 2123-MUMNP-2011-FORM 3(10-12-2013).pdf 2013-12-10
1 2123-MUMNP-2011-FORM-27 [27-09-2024(online)].pdf 2024-09-27
2 2123-MUMNP-2011-FORM 3(10-11-2014).pdf 2014-11-10
2 2123-MUMNP-2011-RELEVANT DOCUMENTS [29-09-2023(online)]-1.pdf 2023-09-29
3 2123-MUMNP-2011-RELEVANT DOCUMENTS [29-09-2023(online)].pdf 2023-09-29
3 2123-MUMNP-2011-FORM 3-(25-04-2015).pdf 2015-04-25
4 2123-MUMNP-2011-RELEVANT DOCUMENTS [27-09-2022(online)].pdf 2022-09-27
4 2123-MUMNP-2011-CORRESPONDENCE(31-08-2015).pdf 2015-08-31
5 2123-MUMNP-2011-RELEVANT DOCUMENTS [09-09-2021(online)].pdf 2021-09-09
5 2123-MUMNP-2011-CORRESPONDENCE(07-12-2015).pdf 2015-12-07
6 2123-MUMNP-2011-FORM 3-(19-03-2016).pdf 2016-03-19
6 2123-MUMNP-2011-CLAIMS(AMENDED)-(25-5-2015).pdf 2018-08-10
7 Petition Under Rule 137 [14-03-2017(online)].pdf 2017-03-14
7 2123-MUMNP-2011-CLAIMS(AMENDED)-(28-5-2015).pdf 2018-08-10
8 Other Patent Document [15-03-2017(online)].pdf 2017-03-15
8 2123-MUMNP-2011-CLAIMS(GRANTED)-(29-3-2017).pdf 2018-08-10
9 2123-MUMNP-2011-CLAIMS(MARKED COPY)-(25-5-2015).pdf 2018-08-10
9 Form 26 [15-03-2017(online)].pdf 2017-03-15
10 2123-MUMNP-2011-CLAIMS(MARKED COPY)-(28-5-2015).pdf 2018-08-10
10 2123-MUMNP-2011_EXAMREPORT.pdf 2018-08-10
11 2123-MUMNP-2011-CLAIMS.pdf 2018-08-10
11 2123-MUMNP-2011-WO INTERNATIONAL PUBLICATION REPORT A1.pdf 2018-08-10
12 2123-MUMNP-2011-CORRESPONDENCE(12-1-2012).pdf 2018-08-10
12 2123-MUMNP-2011-REPLY TO EXAMINATION REPORT(28-5-2015).pdf 2018-08-10
13 2123-MUMNP-2011-CORRESPONDENCE(IPO)-(29-3-2017).pdf 2018-08-10
13 2123-MUMNP-2011-REPLY TO EXAMINATION REPORT(27-4-2015).pdf 2018-08-10
14 2123-MUMNP-2011-CORRESPONDENCE(IPO)-(FER)-(22-1-2015).pdf 2018-08-10
14 2123-MUMNP-2011-REPLY TO EXAMINATION REPORT(25-5-2015).pdf 2018-08-10
15 2123-MUMNP-2011-Correspondence-240715.pdf 2018-08-10
15 2123-MUMNP-2011-OTHERS-240715.pdf 2018-08-10
16 2123-MUMNP-2011-CORRESPONDENCE-251114.pdf 2018-08-10
16 2123-MUMNP-2011-OTHERS(PROOF OF RIGHT)-25112014.pdf 2018-08-10
17 2123-MUMNP-2011-OTHER PCT DOCUMENT.pdf 2018-08-10
17 2123-MUMNP-2011-CORRESPONDENCE.pdf 2018-08-10
18 2123-MUMNP-2011-DESCRIPTION(COMPLETE).pdf 2018-08-10
18 2123-MUMNP-2011-OTHER DOCUMENT.pdf 2018-08-10
19 2123-MUMNP-2011-DESCRIPTION(GRANTED)-(29-3-2017).pdf 2018-08-10
19 2123-MUMNP-2011-OTHER DOCUMENT(27-4-2015).pdf 2018-08-10
20 2123-MUMNP-2011-FORM 1.pdf 2018-08-10
20 2123-MUMNP-2011-Original Under Rule 6(1 A)Form 3-250117.pdf 2018-08-10
21 2123-MUMNP-2011-FORM 18(12-1-2012).pdf 2018-08-10
21 2123-MUMNP-2011-GENERAL POWER OF ATTORNEY(28-5-2015).pdf 2018-08-10
22 2123-MUMNP-2011-FORM 2(GRANTED)-(29-3-2017).pdf 2018-08-10
23 2123-MUMNP-2011-FORM 2(TITLE PAGE)-(GRANTED)-(29-3-2017).pdf 2018-08-10
23 2123-MUMNP-2011-FORM PCT-IPEA-416.pdf 2018-08-10
24 2123-MUMNP-2011-FORM PCT-IPEA-409.pdf 2018-08-10
24 2123-MUMNP-2011-FORM 2(TITLE PAGE).pdf 2018-08-10
25 2123-MUMNP-2011-FORM 5.pdf 2018-08-10
25 2123-MUMNP-2011-FORM 2.pdf 2018-08-10
26 2123-MUMNP-2011-FORM 3(15-2-2012).pdf 2018-08-10
26 2123-MUMNP-2011-FORM 3.pdf 2018-08-10
27 2123-MUMNP-2011-FORM 3(22-5-2014).pdf 2018-08-10
27 2123-MUMNP-2011-Form 3-160816.pdf 2018-08-10
28 2123-MUMNP-2011-FORM 3(22-6-2013).pdf 2018-08-10
28 2123-MUMNP-2011-Form 3-081015.pdf 2018-08-10
29 2123-MUMNP-2011-FORM 3(23-1-2013).pdf 2018-08-10
29 2123-MUMNP-2011-FORM 3(8-8-2012).pdf 2018-08-10
30 2123-MUMNP-2011-FORM 3(23-1-2013).pdf 2018-08-10
30 2123-MUMNP-2011-FORM 3(8-8-2012).pdf 2018-08-10
31 2123-MUMNP-2011-FORM 3(22-6-2013).pdf 2018-08-10
31 2123-MUMNP-2011-Form 3-081015.pdf 2018-08-10
32 2123-MUMNP-2011-FORM 3(22-5-2014).pdf 2018-08-10
32 2123-MUMNP-2011-Form 3-160816.pdf 2018-08-10
33 2123-MUMNP-2011-FORM 3(15-2-2012).pdf 2018-08-10
33 2123-MUMNP-2011-FORM 3.pdf 2018-08-10
34 2123-MUMNP-2011-FORM 2.pdf 2018-08-10
34 2123-MUMNP-2011-FORM 5.pdf 2018-08-10
35 2123-MUMNP-2011-FORM 2(TITLE PAGE).pdf 2018-08-10
35 2123-MUMNP-2011-FORM PCT-IPEA-409.pdf 2018-08-10
36 2123-MUMNP-2011-FORM PCT-IPEA-416.pdf 2018-08-10
36 2123-MUMNP-2011-FORM 2(TITLE PAGE)-(GRANTED)-(29-3-2017).pdf 2018-08-10
37 2123-MUMNP-2011-FORM 2(GRANTED)-(29-3-2017).pdf 2018-08-10
38 2123-MUMNP-2011-FORM 18(12-1-2012).pdf 2018-08-10
38 2123-MUMNP-2011-GENERAL POWER OF ATTORNEY(28-5-2015).pdf 2018-08-10
39 2123-MUMNP-2011-FORM 1.pdf 2018-08-10
39 2123-MUMNP-2011-Original Under Rule 6(1 A)Form 3-250117.pdf 2018-08-10
40 2123-MUMNP-2011-DESCRIPTION(GRANTED)-(29-3-2017).pdf 2018-08-10
40 2123-MUMNP-2011-OTHER DOCUMENT(27-4-2015).pdf 2018-08-10
41 2123-MUMNP-2011-DESCRIPTION(COMPLETE).pdf 2018-08-10
41 2123-MUMNP-2011-OTHER DOCUMENT.pdf 2018-08-10
42 2123-MUMNP-2011-CORRESPONDENCE.pdf 2018-08-10
42 2123-MUMNP-2011-OTHER PCT DOCUMENT.pdf 2018-08-10
43 2123-MUMNP-2011-CORRESPONDENCE-251114.pdf 2018-08-10
43 2123-MUMNP-2011-OTHERS(PROOF OF RIGHT)-25112014.pdf 2018-08-10
44 2123-MUMNP-2011-Correspondence-240715.pdf 2018-08-10
44 2123-MUMNP-2011-OTHERS-240715.pdf 2018-08-10
45 2123-MUMNP-2011-CORRESPONDENCE(IPO)-(FER)-(22-1-2015).pdf 2018-08-10
45 2123-MUMNP-2011-REPLY TO EXAMINATION REPORT(25-5-2015).pdf 2018-08-10
46 2123-MUMNP-2011-REPLY TO EXAMINATION REPORT(27-4-2015).pdf 2018-08-10
46 2123-MUMNP-2011-CORRESPONDENCE(IPO)-(29-3-2017).pdf 2018-08-10
47 2123-MUMNP-2011-CORRESPONDENCE(12-1-2012).pdf 2018-08-10
47 2123-MUMNP-2011-REPLY TO EXAMINATION REPORT(28-5-2015).pdf 2018-08-10
48 2123-MUMNP-2011-CLAIMS.pdf 2018-08-10
48 2123-MUMNP-2011-WO INTERNATIONAL PUBLICATION REPORT A1.pdf 2018-08-10
49 2123-MUMNP-2011-CLAIMS(MARKED COPY)-(28-5-2015).pdf 2018-08-10
49 2123-MUMNP-2011_EXAMREPORT.pdf 2018-08-10
50 2123-MUMNP-2011-CLAIMS(MARKED COPY)-(25-5-2015).pdf 2018-08-10
50 Form 26 [15-03-2017(online)].pdf 2017-03-15
51 2123-MUMNP-2011-CLAIMS(GRANTED)-(29-3-2017).pdf 2018-08-10
51 Other Patent Document [15-03-2017(online)].pdf 2017-03-15
52 2123-MUMNP-2011-CLAIMS(AMENDED)-(28-5-2015).pdf 2018-08-10
52 Petition Under Rule 137 [14-03-2017(online)].pdf 2017-03-14
53 2123-MUMNP-2011-CLAIMS(AMENDED)-(25-5-2015).pdf 2018-08-10
53 2123-MUMNP-2011-FORM 3-(19-03-2016).pdf 2016-03-19
54 2123-MUMNP-2011-RELEVANT DOCUMENTS [09-09-2021(online)].pdf 2021-09-09
54 2123-MUMNP-2011-CORRESPONDENCE(07-12-2015).pdf 2015-12-07
55 2123-MUMNP-2011-RELEVANT DOCUMENTS [27-09-2022(online)].pdf 2022-09-27
55 2123-MUMNP-2011-CORRESPONDENCE(31-08-2015).pdf 2015-08-31
56 2123-MUMNP-2011-RELEVANT DOCUMENTS [29-09-2023(online)].pdf 2023-09-29
56 2123-MUMNP-2011-FORM 3-(25-04-2015).pdf 2015-04-25
57 2123-MUMNP-2011-RELEVANT DOCUMENTS [29-09-2023(online)]-1.pdf 2023-09-29
57 2123-MUMNP-2011-FORM 3(10-11-2014).pdf 2014-11-10
58 2123-MUMNP-2011-FORM 3(10-12-2013).pdf 2013-12-10
58 2123-MUMNP-2011-FORM-27 [27-09-2024(online)].pdf 2024-09-27

ERegister / Renewals

3rd: 22 Apr 2017

From 13/04/2012 - To 13/04/2013

4th: 22 Apr 2017

From 13/04/2013 - To 13/04/2014

5th: 22 Apr 2017

From 13/04/2014 - To 13/04/2015

6th: 22 Apr 2017

From 13/04/2015 - To 13/04/2016

7th: 22 Apr 2017

From 13/04/2016 - To 13/04/2017

8th: 22 Apr 2017

From 13/04/2017 - To 13/04/2018

9th: 14 Mar 2018

From 13/04/2018 - To 13/04/2019

10th: 20 Mar 2019

From 13/04/2019 - To 13/04/2020

11th: 26 Feb 2020

From 13/04/2020 - To 13/04/2021

12th: 24 Feb 2021

From 13/04/2021 - To 13/04/2022

13th: 25 Mar 2022

From 13/04/2022 - To 13/04/2023